common stock, $.0001 par value
- Symbol
- SIGA
- Exchange
- NASDAQ
- Classification
- COMMON
- Status
- Current
Current Report · Items 2.02, 9.01 · 8-K
SIGANASDAQEQUITYCurrent
Item 2.02 Results of Operations and Financial Condition. On March 10, 2026, SIGA Technologies, Inc. (the “Company”) issued a press release (the “Press Release”) announcing its financial results for the three and twelve months ended December 31, 2025.…
SIGA is a commercial-stage pharmaceutical company and leader in global health focused on the development of innovative medicines to treat and prevent infectious diseases. With a primary focus on smallpox, we are dedicated to protecting humanity against the world’s most severe infectious diseases, including those that occur naturally, accidentally, or intentionally. Through partnerships with governments and public health agencies, we work to build a healthier and safer world by providing essential countermeasures against these global health threats. For more information about SIGA, visit www.siga.com.
SIGA TECHNOLOGIES INC. · 8-K · Filed 2026-03-10
EX-99.1 2 ef20067458_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Press Release SIGA Reports Financial Results for Three and Twelve Months Ended December 31, 2025 and Provides Business Update Generated TPOXX Product Revenues of $88 Million in 2025 Received $13 Million International Procurement Order for Oral TPOXX in January 2026 Corporate Update Conference Call Today at 4:30 PM ET NEW YORK -- SIGA Technologies, Inc. (SIGA) (Nasdaq: SIGA), a commercial-stage pharmaceutical company, today reported financial results for the three and twelve months ended December 31, 2025. “In 2025, we continued to advance SIGA's key long-term priorities, including securing $27 million in additional U.S. Government funding to support development activities, while generating $88 million in product revenues and $24 million in pre-tax operating income," stated Diem Nguyen, Chief Executive Officer. "In 2026, we are focused on building on our long-standing track record as a successful partner to the U.S. Government and international governments to secure new procurement contracts and orders that will serve as the foundation of our revenues in the years ahead. Accordingly, in January, we started…
Open exhibit ↗